| Indicators | Browse All

Q/C Technologies, Inc. (QCLS)

Technology | Computer Hardware | New York, United States | NasdaqCM
2.35 USD -0.02 (-0.844%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 2.35

Short-term:★☆☆☆☆Long-term:☆☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 4:55 a.m. EDT

The investment case here is nonexistent due to a catastrophic multi-year decline. The price has erased nearly 100% of its value over the last nine years, with every single year showing negative returns. This is not a temporary setback; it is a structural implosion where the market has consistently rejected the business model for a decade. Fundamentally, the company is bleeding cash aggressively, reporting massive losses in both assets and equity, while burning through free cash flow with no visible path to profitability. The recent news of ending a key deal and the lack of analyst coverage further confirm that the core operations are failing to generate value. While the stock recently found a floor near $2.50, trading at less than book value, this is a classic value trap where the low price reflects the reality of a dying business rather than a bargain opportunity. With no dividend to provide income and a balance sheet that cannot support continued operations without external capital, there is no rational basis for a long-term hold. The short-term outlook remains bleak as the company struggles to navigate its cash burn and operational challenges.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.203075
AutoTheta0.211034
MSTL0.232292
AutoARIMA0.248717

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 34%
H-stat 37.32
Ljung-Box p 0.000
Jarque-Bera p 0.241
Excess Kurtosis -1.23
Attribute Value
Sector Technology
Debt to Equity Ratio 1.946
Market Cap 19,246,118
Beta 2.11
Previous Name MyMD Pharmaceuticals, Inc.
Website https://www.qctechnologies.com

Info Dump

Attribute Value
52 Week Change -0.38157892
Address1 1,185 Avenue of the Americas
Address2 Suite 249
All Time High 6,566,400.0
All Time Low 2.3
Ask 2.49
Ask Size 10
Average Daily Volume10 Day 142,260
Average Daily Volume3 Month 212,690
Average Volume 212,690
Average Volume10Days 142,260
Beta 2.113
Bid 1.7
Bid Size 2
Book Value 1.947
City New York
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 2.35
Current Ratio 3.293
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 2.4
Day Low 2.32
Debt To Equity 1.946
Display Name Q/C
Ebitda Margins 0.0
Enterprise Value 11,757,799
Eps Trailing Twelve Months -90.09
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 3.176
Fifty Day Average Change -0.8260002
Fifty Day Average Change Percent -0.26007563
Fifty Two Week Change Percent -38.15789
Fifty Two Week High 8.94
Fifty Two Week High Change -6.5899997
Fifty Two Week High Change Percent -0.7371365
Fifty Two Week Low 2.3
Fifty Two Week Low Change 0.049999952
Fifty Two Week Low Change Percent 0.02173911
Fifty Two Week Range 2.3 - 8.94
Financial Currency USD
First Trade Date Milliseconds 1,390,487,400,000
Float Shares 8,113,263
Free Cashflow -5,953,920
Full Exchange Name NasdaqCM
Full Time Employees 3
Fullday Change -0.02
Fullday Change Percent -0.843881
Fullday Price 2.35
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.07531
Held Percent Institutions 0.09020001
Implied Shares Outstanding 8,189,838
Industry Computer Hardware
Industry Disp Computer Hardware
Industry Key computer-hardware
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,756,771,200
Last Split Factor 1:100
Long Business Summary Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
Long Name Q/C Technologies, Inc.
Market us_market
Market Cap 19,246,118
Market State CLOSED
Max Age 86,400
Message Board Id finmb_694917951
Most Recent Quarter 1,782,777,600
Name Change Date 2,026-08-29
Net Income To Common -18,341,612
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 19,573,712
Open 2.39
Operating Cashflow -9,465,108
Operating Margins 0.0
Payout Ratio 0.0
Phone 856 848 8698
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 2.35
Post Market Time 1,787,961,535
Prev Name MyMD Pharmaceuticals, Inc.
Previous Close 2.37
Price Hint 4
Price To Book 1.206985
Profit Margins 0.0
Quick Ratio 3.086
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.02
Regular Market Change Percent -0.843881
Regular Market Day High 2.4
Regular Market Day Low 2.32
Regular Market Day Range 2.32 - 2.4
Regular Market Open 2.39
Regular Market Previous Close 2.37
Regular Market Price 2.35
Regular Market Time 1,787,947,200
Regular Market Volume 106,940
Return On Assets -0.33443
Return On Equity -1.08004
Sand P52 Week Change 0.20204377
Sector Technology
Sector Disp Technology
Sector Key technology
Shares Outstanding 8,189,838
Shares Percent Shares Out 0.1752
Shares Short 1,435,248
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 1,598,772
Short Name Q/C Technologies, Inc.
Short Percent Of Float 0.8015
Short Ratio 9.14
Source Interval 15
State NY
Symbol QCLS
Total Cash 10,987,394
Total Cash Per Share 1.342
Total Debt 371,171
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -90.09
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 3.847
Two Hundred Day Average Change -1.497
Two Hundred Day Average Change Percent -0.3891344
Type Disp Equity
Volume 106,940
Website https://www.qctechnologies.com
Zip 10,036